ing; occult malignancy Peripheral blood or bone marrow donors undergo a rigorous screening process prior to donations to assess whether they can safely donate, their graft will be safe for the recipient and they understand the risks and benefits of stem cell donation. This work-up usually includes obtaining a medical history, physical examination and investigations, which in most centers include laboratory parameters such as CBC, blood chemistry, and testing for transmissible diseases.
1 Chest X-rays and electrocardiograms are routinely carried out in some centers. Few centers perform bone marrow aspirates as part of the donor work-up. At Princess Margaret Hospital, bone marrow aspirates are performed routinely as part of the pre transplant assessment on all potential donors aged more than 16 years and examined for morphology and hemopoietic progenitor cell reserve using clonogenic progenitor assays.
Over time as stem cell transplantation has evolved, median age of recipients and their related donors has increased. 2 With the advent of nonmyeloablative allogeneic stem cell transplantation, age limits of recipients for transplantation have further increased. This has led to a growing number of elderly donors and an increased risk that a related donor may harbor a medical condition that would exclude bone marrow donation. In the more recent past, we have diagnosed hematological malignancies on three potential donors who presented with no clinical symptoms and virtually normal blood counts but had abnormal bone marrow aspirates and inferior hemopoietic colony growth. These individuals were subsequently excluded from the donation process.
Patients and methods
All three patients were screened as potential donors for allogeneic stem cell transplantation at Princess Margaret Hospital in the year 2002. Patient data was summarized by review of chart and computer records.
Bone marrow aspirates were evaluated morphologically and by cell culture using the CFU-GEMM (colony forming unit-granulocyte, erythroid, megakaryocyte, macrophage) assay to assess the frequency of progenitors using methyl cellulose medium with human plasma and recombinant cytokines, which support growth of CFU-GEMM, CFU-GM, CFU-MEG and BFU-E (burst forming uniterythroid). 3, 4 Bone marrow-derived clonogenic assays of 20 normal donors were cultured during the same time period in 2002 and mean values of this group were compared with mean values of the three study patients using the Student's t-test.
5
The pre bone marrow transplant work-up of normal donors for related transplants at Princess Margaret Hospital consists of the following: (1) history and physical examination, (2) laboratory investigations including CBC, differential count, electrolytes, creatinine, glucose, liver enzymes, bilirubin, calcium, phosphorus, magnesium, protein, albumin, INR, PTT, ABO grouping, Rhesus grouping, sickle cell screen in donors at risk, serological screens for hepatitis B, C, HIV, CMV, HTLV1, West Nile virus (WNV), PCR testing for WNV, VDRL and molecular chimerism studies, (3) bone marrow aspirate for morphology and in vitro cell culture, (4) electrocardiogram for patients over age 50 years and (5) other investigations as clinically indicated.
Case 1
This 65-year-old man was evaluated for peripheral stem cell donation for the purpose of a nonmyeloablative stem cell transplant to his 58-year-old brother who was diagnosed with multiple myeloma (MM). His past medical history was unremarkable. He denied any constitutional symptoms or bony pains. His physical examination in the bone marrow transplant clinic was unremarkable. Laboratory investigations showed an Hb of 127 g/l, leukocyte count of 6.0 Â 10 9 /l and a platelet count of 269 Â 10 9 /l. Blood chemistry showed normal values for serum creatinine, liver enzymes and calcium. A bone marrow aspirate was obtained, which demonstrated the presence of 12% of atypical appearing plasma cells. Further investigations following the bone marrow test showed serum protein electrophoresis and immunofixation demonstrating a monoclonal paraprotein IgG kappa of 19.6 g/l (normal range 4.6-13.3 g/l) and a beta 2 microglobulin level of 168 nmol/l (normal range:o219). Skeletal survey was normal. Del (13q), a cytogenetic abnormality associated with MM, was not present. The patient's investigations were considered most consistent with smouldering MM. Clonogenic progenitor assay evaluation showed the presence of 144 CFU-C, 151 BFU-E, 12 CFU-MEG and four CFU-GEMM (Table 1) .
Case 2
This 72-year-old man was evaluated for bone marrow donation to his 64-year-old brother who was diagnosed with chronic lymphocytic leukemia (CLL) in Richters transformation. His past medical history was unremarkable besides a history of mild asthma bronchiale. He denied any constitutional symptoms. Physical examination was unremarkable. Laboratory investigations showed an Hb of 150 g/l, a leukocyte count of 10.1 Â 10 9 /l and a lymphocyte count of 4.0 Â 10 9 /l; platelets were at 189 Â 10 9 /l. Bone marrow aspiration showed increased cellularity with 50-60% small lymphocytes. A repeat bone marrow aspirate and biopsy were obtained and demonstrated nodular and interstitial infiltrates with small lymphocytes at approx. 60%. Flow cytometry showed lymphocytes to be positive for CD5, CD20, CD23, CD38 and monoclonal kappa, consistent with the diagnosis of CLL. Clonogenic precursor assay showed the presence of 50 CFU-C, 43 BFU-E, 0 CFU-MEG and eight CFU-GEMM (Table 1) .
Case 3
This 42-year-old man was evaluated for bone marrow donation to his 45-year-old brother who had been diagnosed with myelodysplastic syndrome (MDS). Patient's history was positive for substance abuse in the remote past. He had been feeling well with no constitutional symptoms in the recent past. His physical examination and chest X-ray were unremarkable. His initial laboratory investigations showed an Hb of 139 g/l with normal MCV, leukocyte count of 8.4 Â 10 9 /l with normal differential count and a platelet count of 263 Â 10 9 /l. Blood film review was normal. His serum was positive for hepatitis C antibody. The bone marrow aspirate showed an increase of small lymphocytes to more than 50%. Repeat CBC showed an Hb of 129 g/l with normal MCV, leukocyte count of 7.1 Â 10 9 /l with normal differential count and a platelet count of 285 Â 10 9 /l. A repeat bone marrow aspirate and biopsy were performed. The biopsy revealed the presence of a lymphoid aggregate. Flow cytometry revealed a polyclonal lymphoid population. Morphology of cell lineages showed mild dyserythropoiesis. No ring sideroblasts were seen. Cytogenetic studies revealed the presence of t(2:11) and del (5q). These cytogenetic abnormalities are consistent with MDS. Clonogenic precursor assay showed the presence of 191 CFU-C, 26 BFU-E, two CFU-MEG and two CFU-GEMM (Table 1) .
Discussion
It is the objective of the donor work-up to assess suitability for stem cell donation in an effort to protect the donor and the recipient. Little information is available as to what screening examinations potential stem cell donors should undergo.
At Princess Margaret Hospital, screening of adult donors includes a bone marrow aspirate, which is examined for Table 1 Frequency of clonogenic hematopoietic progenitors in three potential donors and 20 normal donors (median values given) using the CFU-GEMM assay
CFU-GM
BFU-E CFU-MEG CFU-GEMM The reported three cases demonstrate identification of occult malignancies in patients who did not have any other indication for such a problem. A coexisiting malignancy is considered an exclusion criterion for stem cell donation because of the potential for transmission of this disease to the recipient and the risk of acceleration of this disease in the immunosuppressed host leading to devastating consequences. There are to the best of our knowledge no previous reports of detection of malignancy in potential transplant recipients by screening bone marrow examinations. Transmission of donor-derived malignancy to a transplant recipient through the transplant has been described. 6 The scenario of a donor who had a normal physical examination, normal blood counts and blood film was presented. At the time of the transplant, it was noted that the graft contained 38% blast cells consistent with the diagnosis of acute myeloid leukemia. 6 The recipient acquired donor-derived AML and died due to toxicity following a second transplant from another donor. Peters et al 7 describe the case of a potential donor who had been identified with a monoclonal gammopathy of unknown significance based on screening serum protein electrophoresis. There is the report of a potential donor who had been diagnosed with Gaucher's disease on screening bone marrow examination.
8 Donor cell-derived malignancies occurring late in recipients post bone marrow transplant have also been described. 9 At our institution, a patient with CML developed AML post transplant. With molecular methods it was determined that the secondary leukemia developed in cells of donor origin. 9 In addition, a patient transplanted at Princess Margaret Hospital for CML had developed overt MM years post transplant. This occurred following the patients donor having developed the same disease (J Lipton, Princess Margaret Hospital, personal communication).
The upper age limit for transplant recipients is increasing with so-called reduced intensity transplants. With the rising age of transplant recipients, the age of potential related donors will also likely be elevated. A number of slowly developing hematological malignancies, for example CLL, MM and MDS, occur more frequently in the older age group. Two of the three affected donors in this report were older than 60. Because of this, it is reasonable to screen potential donors for hematological malignancies particularly in the older age group. A familial occurrence of hematological malignancies like MM, non-Hodgkin's lymphoma and MDS has been described. 10, 11, 12 Of note is that in our series of patients, the donor and recipient in all three cases were diagnosed with the same hematological malignancy. This leads to the consideration that in addition to older donors particularly in donors with potential for familial malignancies more extensive screening investigations including serum protein electrophoresis and bone marrow aspiration may be reasonable. Based on the three cases presented, however, due to the small number no firm recommendations can be made. Of note is that serum protein electrophoresis as a screening tool would have detected the occult malignancy in one of the three potential donors.
A disadvantage of bone marrow aspirates as part of donor screening is the considerably increased cost and potential morbidity. Also prospective donors may be more reluctant to be involved in the process facing the prospect of a bone marrow aspirate.
Bone marrow aspirates in this study were only performed on related donors. It would be more difficult to add this screening tool to the examination of unrelated donors.
Clonogenic precursor assays have been performed on each of the potential three donors described in this study.
Mean colony values of donors have been compared to mean colony growth of 20 normal individuals whose bone marrow was cultured in the laboratory during the same time period. A statistically significant reduction of colony growth in three lineages comparing the three potential donors with 20 normal donors was noted ( Table 1 ), suggesting that the coexisting hematological malignancy interfered with normal hemopoietic colony formation in these individuals. Clonogenic precursor assays may be used as additional tool besides bone marrow morphology to screen for bone marrow abnormalities in potential donors.
In conclusion, particularly in older donors and donors with potential for familial malignancies, more extensive screening investigations including bone marrow aspiration may be reasonable to investigate for occult hematological malignancies prior to stem cell donation. Clonogenic precursor assays can be a useful screening tool to assess bone marrow abnormalities.
